Back to top
more

BioNTech (BNTX)

(Delayed Data from NSDQ)

$107.34 USD

107.34
840,684

-0.16 (-0.15%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $107.40 +0.06 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View

by Zacks Equity Research

MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.

Zacks Equity Research

Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect

by Zacks Equity Research

ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.

Kinjel Shah headshot

Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings

by Kinjel Shah

PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.

Zacks Equity Research

Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View

by Zacks Equity Research

BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.

Zacks Equity Research

BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know

by Zacks Equity Research

Does BioNTech SE Sponsored ADR (BNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Perrigo to Report Q2 Earnings: What's in Store for the Stock?

by Zacks Equity Research

PRGO eyes Q2 results, which are likely to show sales of $1.08 billion, as investors await updates on its Kairos deal and macro pressures.

Zacks Equity Research

Best Momentum Stocks to Buy for July 29th

by Zacks Equity Research

GDS, U and BNTX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 29, 2025.

Zacks Equity Research

Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?

by Zacks Equity Research

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.

Zacks Equity Research

New Strong Buy Stocks for July 29th

by Zacks Equity Research

AVO, PGR, BNTX, U and GDS have been added to the Zacks Rank #1 (Strong Buy) List on July 29, 2025.

Ekta Bagri headshot

Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?

by Ekta Bagri

BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.

Ekta Bagri headshot

Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?

by Ekta Bagri

BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.

Zacks Equity Research

Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how BioNTech SE Sponsored ADR (BNTX) and EUROFINS SCIENT (ERFSF) have performed compared to their sector so far this year.

Kinjel Shah headshot

Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings

by Kinjel Shah

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Ekta Bagri headshot

Will Increased Expenses Affect Bristol Myers' Performance?

by Ekta Bagri

BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.

Zacks Equity Research

MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients

by Zacks Equity Research

Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.

Ekta Bagri headshot

BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?

by Ekta Bagri

BMY loses 16.3% YTD as pipeline setbacks and generic pressure offset gains from new drug approvals and sales.

Zacks Equity Research

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

by Zacks Equity Research

CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.

Zacks Equity Research

BMY Reports Positive Data on Sotyktu From Arthritis Study

by Zacks Equity Research

Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.

Ekta Bagri headshot

BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?

by Ekta Bagri

BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure

Zacks Equity Research

Bristol Myers Collaborates With BNTX for Oncology Candidate

by Zacks Equity Research

BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors.

Zacks Equity Research

Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results

by Zacks Equity Research

SMMT plunges 31% as its NSCLC drug shows strong PFS but misses statistical significance on survival data.

Zacks Equity Research

MRNA Seeks FDA Nod for Updated COVID-19 Vaccine

by Zacks Equity Research

Moderna files with FDA for updated Spikevax aimed at the LP.8.1 variant, which makes up 70% of U.S. COVID-19 cases.

Sundeep Ganoria headshot

MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots

by Sundeep Ganoria

Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.

Zacks Equity Research

Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales

by Zacks Equity Research

PFE beats first-quarter estimates for earnings but misses the same for sales. It maintains 2025 guidance.

Zacks Equity Research

Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season?

by Zacks Equity Research

Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.